Springbok Capital Management Has Lowered Stake in Liberty Global Plc (LBTYK) as Stock Declined; Ra Capital Management Has Increased Aveo Pharmaceuticals (AVEO) Stake by $8.68 Million

February 25, 2018 - By Hazel Jackson

Peter Kolchinsky increased its stake in Aveo Pharmaceuticals Inc (AVEO) by 34.3% based on its latest 2017Q3 regulatory filing with the SEC. Ra Capital Management Llc bought 2.89 million shares as the company’s stock declined 7.05% while stock markets rallied. The hedge fund run by Peter Kolchinsky held 11.33M shares of the health care company at the end of 2017Q3, valued at $41.35 million, up from 8.44 million at the end of the previous reported quarter. Ra Capital Management Llc who had been investing in Aveo Pharmaceuticals Inc for a number of months, seems to be bullish on the $440.86M market cap company. The stock increased 0.35% or $0.01 during the last trading session, reaching $2.87. About 1.46M shares traded. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) has declined 16.67% since February 25, 2017 and is downtrending. It has underperformed by 33.37% the S&P500.

Gavin Saitowitz decreased its stake in Liberty Global Plc (LBTYK) by 95.17% based on its latest 2017Q3 regulatory filing with the SEC. Springbok Capital Management Llc sold 14,787 shares as the company’s stock declined 17.26% while stock markets rallied. The hedge fund run by Gavin Saitowitz held 750 shares of the television services company at the end of 2017Q3, valued at $25,000, down from 15,537 at the end of the previous reported quarter. Springbok Capital Management Llc who had been investing in Liberty Global Plc for a number of months, seems to be less bullish one the $25.62 billion market cap company. The stock increased 1.26% or $0.39 during the last trading session, reaching $31.37. About 2.37M shares traded. Liberty Global plc (NASDAQ:LBTYK) has declined 6.78% since February 25, 2017 and is downtrending. It has underperformed by 23.48% the S&P500.

Springbok Capital Management Llc, which manages about $1.29B and $1.11B US Long portfolio, upped its stake in Boston Properties Inc (NYSE:BXP) by 13,417 shares to 28,512 shares, valued at $3.50 million in 2017Q3, according to the filing. It also increased its holding in Timkensteel Corp (NYSE:TMST) by 19,300 shares in the quarter, for a total of 21,500 shares, and has risen its stake in American Intl Group Inc (Call) (NYSE:AIG).

Investors sentiment increased to 1.32 in 2017 Q3. Its up 0.23, from 1.09 in 2017Q2. It is positive, as 10 investors sold AVEO shares while 12 reduced holdings. 14 funds opened positions while 15 raised stakes. 59.90 million shares or 5.78% less from 63.58 million shares in 2017Q2 were reported. Gsa Prtn Ltd Liability Partnership holds 0% in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) or 14,700 shares. Sanctuary Wealth Limited Liability Company stated it has 2,042 shares. 683 Mgmt Lc has invested 0.96% in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO). Ra Capital Ltd Liability Com holds 3.74% in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) or 11.33M shares. Point72 Asset Management Limited Partnership invested 0% of its portfolio in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO). Gemmer Asset Mngmt Ltd Limited Liability Company accumulated 1,939 shares. Essex Investment Management Limited Com holds 150,620 shares or 0.07% of its portfolio. New Leaf Venture Prtnrs Lc owns 3.96% invested in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) for 2.34M shares. Geode Cap Management Ltd Liability Corporation holds 627,340 shares or 0% of its portfolio. Guggenheim Capital Llc holds 20,642 shares. Moreover, Northern Tru has 0% invested in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO). 25,000 are held by Clear Harbor Asset Mgmt. Deer Vi Co Limited Liability Company reported 100% stake. Nea Management Co Limited Liability Co reported 2.09% stake. Excalibur Management Corp holds 0.03% of its portfolio in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) for 11,000 shares.

Among 3 analysts covering AVEO Pharmaceuticals (NASDAQ:AVEO), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. AVEO Pharmaceuticals had 12 analyst reports since March 30, 2016 according to SRatingsIntel. On Thursday, May 19 the stock rating was initiated by Piper Jaffray with “Overweight”. The stock has “Outperform” rating by FBR Capital on Wednesday, March 30. The stock of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) earned “Buy” rating by Piper Jaffray on Thursday, October 5. FBR Capital maintained the stock with “Buy” rating in Tuesday, January 16 report. FBR Capital maintained the shares of AVEO in report on Monday, February 12 with “Buy” rating. The company was maintained on Monday, June 26 by FBR Capital. Piper Jaffray maintained it with “Buy” rating and $3.5000 target in Wednesday, August 9 report. The firm has “Buy” rating by FBR Capital given on Thursday, December 7. The rating was upgraded by Piper Jaffray on Monday, August 28 to “Buy”.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>